Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. The request metadata identifies Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd. as the registrant.
Reporting period: Month of May 2023, Report No. 2. Filed May 5, 2023, under Commission file number 001-39957. The registrant files annual reports on Form 20-F.
Business Context and Corporate Change
On May 1, 2023, Chad Hellmann resigned as Chief Financial Officer. He agreed to provide transition services through May 31, 2023.
The filing states that the resignation was not due to any material disagreement with the company regarding its operations, policies, or practices. The company expressed appreciation for his contributions.
Financial Metrics and Liquidity
This Form 6-K does not provide revenue, profit, cash flow, margin, debt, liquidity, operating, or other financial metrics.
Material Changes Versus the Prior Comparable Period
The filing reports the CFO resignation and related transition arrangement. No comparative-period financial information or other material operating changes are provided.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, outlook, management forecast, risk update, contingency, or unusual financial item is disclosed.
The report is incorporated by reference into the company’s Form F-3 registration statements filed under file numbers 333-262489, 333-268690, and 333-269220, to the extent not superseded by later filings.
Investor Verification Items
- Verify the identity of the registrant, because the supplied metadata names Newcelx Ltd. while the filing names NLS Pharmaceutics Ltd.
- Confirm whether a permanent CFO successor was appointed after the transition period ended on May 31, 2023.
- Review subsequent SEC filings for any additional management changes or financial disclosures.
- Assess the potential effect, if any, of the CFO transition on financial reporting and internal controls.